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Abstract
Objectives-The main neuropathological
feature in Parkinson's disease is a severe
degeneration of the dopaminergic neu-
rons in the substantia nigra resulting in a
loss ofdopamine (DA) transporters in the
striatum. [1231]_CIT single photon emis-
sion computed tomography (SPECT)
studies have demonstrated this loss of
striatal DA transporter content in
Parkinson's disease in vivo. However,
studies with this radioligand also showed
that an adequate imaging of the striatal
DA transporter content could only be per-
formed on the day after the injection of
radioligand, which is not convenient for
outpatient evaluations. Recently, a new
radioligand ["23I]FP-CIT, with faster
kinetics than ,-CIT, became available for
imaging of the DA transporter with
SPECT, and the applicability of this lig-
and was tested in patients with early and
advanced Parkinson's disease, using a
one day protocol.
Methods-['23I]FP-CIT SPECT was per-
formed in six patients with early and 12
patients with advanced Parkinson's dis-
ease, and in six age matched healthy vol-
unteers.
Results-Compared with an age matched
control group striatal ["23I]FP-CIT uptake
in patients with Parkinson's disease was
decreased, and this result was measurable
three hours after injection of the radioli-
gand. In the Parkinson's disease group
the uptake in the putamen was reduced
more than in the caudate nucleus. The
contralateral striatal uptake of ["23I]FP-
CIT was significantly lower than the ipsi-
lateral striatal uptake in the Parkinson's
disease group. Specific to non-specific
striatal uptake ratios correlated with the
Hoehn and Yahr stage. A subgroup of
patients with early Parkinson's disease
also showed significantly lower uptake in
the putamen and lower putamen:caudate
ratios than controls.
Conclusion--["23IFP-CIT SPECT allows
a significant discrimination between
patients with Parkinson's disease and age
matched controls with a one day protocol,
which will be to great advantage in outpa-
tient evaluations.
(J Neurol Neurosurg Psychiatry 1997;62:133-140)
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Parkinson's disease is a severe, progressive
neurodegenerative disorder which is neu-
ropathologically characterised by a degenera-
tion of the dopamine (DA) containing cells in
the substantia nigra.' As a result of this cell
loss, there is a substantial decrease in the DA
content of the striatum, and a corresponding
loss of DA transporters.23 The striatum is the
main output region of the substantia nigra.
Single photon emission computed tomogra-
phy (SPECT) and PET provide unique
opportunities of examining DAergic systems
in the human brain in vivo. Visualisation of the
DA transporter with various ligands in
SPECT and PET imaging has been intro-
duced as a valuable tool for the in vivo evalua-
tion of the integrity of the nigrostriatal
DAergic pathway in Parkinson's disease. PET
studies with "IC-labelled nomifensine have dis-
criminated between groups of patients with
Parkinson's disease and healthy volunteers.'6
Recently, radiolabelled cocaine-like ligands for
in vivo imaging of the DA transporter were
introduced. In particular, SPECT with the
'23I-labelled cocaine analogue ,3-CIT (or RTI-
55) showed a dramatic loss of striatal DA
transporters in patients with Parkinson's dis-
ease with high signal to noise ratios.7-" PET in
Parkinson's disease, using the "'C-labelled
cocaine analogue WIN 35 428 (or f3-CFT),
showed much lower signal to noise ratios,
although patients could clearly be discrimi-
nated from controls." 12 The use of ["IC],3
CIT in PET imaging failed to significantly
discriminate between small groups of patients
with early Parkinson's disease and healthy
controls. 12
Uptake of ['231]fi-CIT in the human stria-
tum is characterised by very slow kinetics,
which is a serious drawback. Radioactivity in
the striatum increases for 20 hours after injec-
tion of this radioligand, and stabilises there-
after up to 30 hours. The stable level of
radioactivity between 20 and 30 hours satisfies
conditions of prolonged equilibrium."3
However, this indicates that an image acquisi-
tion should be performed on the day after the
injection, which is not convenient for outpa-
tient evaluation. Moreover, it is not optimal
for counting statistics as the half life of 123I is
about 13 hours.
N-o-fluoroalkyl analogues of 3-CIT have
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recently been synthesised in an effort to pro-
duce ligands for the DA transporter with faster
kinetics than for /-CIT.14 16 This may provide
the ability to perform an adequate image
acquisition on the day of the injection of
the radioligand. One of these new compounds,
N-o--fluoropropyl-2,f-carbomethoxy-3,B (4-iodo-
phenyl)tropane) (FP-CIT), has been labelled
with 123I for SPECT or with "IC for PET. 15 17
['23I]FP-CIT (or ,B3CIT-FP) has been tested in
baboons and humans as a tracer for the DA
transporter.'4 15 18 19 These studies showed high
brain uptake, faster kinetics than for ,B-CIT,
an early peak in striatal specific activity (sev-
eral hours postinjection), and high striatal to
occipital cortex ratios (high target to non-tar-
get ratios). In addition, in vivo displacement
studies in the monkey showed that striatal
uptake of ["C]FP-CIT was primarily due to
DA transporter labelling.'7 Thus ['231]FP-CIT
is a promising SPECT probe for measuring
DA transporters in living human brain non-
invasively.
The aim of the present study was to investi-
gate if the striatal DA deficiency of
Parkinson's disease could be demonstrated
using [123I]FP-CIT, and whether this new
radioligand is able to discriminate presynaptic
DAergic hypofunction in patients with early
Parkinson's disease from that in age matched
healthy controls by using a one day protocol.
Subjects and methods
SUBJECTS
Six healthy controls and 18 patients with clini-
cally established Parkinson's disease according
to the UK Parkinson's Disease Society Brain
Bank criteria, were selected (table 1). The
controls were healthy volunteers with no evi-
dence of a neurological or a psychiatric disease.
The controls were age matched (mean age
57 5, range 44-83 years) with the group of
patients with Parkinson's disease (mean age
60-8, range 40-77 years) because [1231]3 -CIT
SPECT investigations in healthy human sub-
jects showed reductions of tracer uptake with
increasing age, compatible with postmortem
findings ofDA transporter loss.21 22
A neurological examination of the patients
was performed (by GT and JDS) to assess the
severity of motor signs according to the motor
section of the Unified Parkinson's Disease
Rating Scale (UPDRS),23 and the scores
ranged from 8 to 55. The stage of illness was
determined from the Hoehn and Yahr staging
scale,24 and ranged from I to IV. In patients
with severe on/off fluctuations, the motor signs
were scored during the worst off period
(defined according to Langston et al25; table 1).
The highest values, both for the Hoehn and
Yahr scale and the UPDRS, were found in five
patients with Parkinson's disease with on/off
fluctuations. At the time of the SPECT experi-
ments the patients under DAergic medication
used either only levodopa or both levodopa and
DA receptor agonists (table 1).
The medical ethics committee gave permis-
sion for the study. All participants gave written
informed consent.
METHODS
SPECT camera and reconstruction
For the SPECT a brain dedicated SPECT sys-
tem, the Strichman Medical Equipment 81OX
linked to a MacIntosh II (Appleg) computer,
was used. The Strichman camera consists of 12
individual crystals, each equipped with a focus-
ing collimator. The transaxial resolution of this
camera is 7-6 mm full width at half maximum
of a line source in air (FWHM), and the axial
resolution is 13-5 mm FWHM. The energy
window was set at 135-190 keV. Data acquisi-
tion took place in a 128 x 128 matrix. A linear
attenuation correction, based on an absorption
length of 95 mm, was applied in all studies.
The attenuation elliptic contour corresponded
to the diameter of the skull, as automatically
estimated by the software. The images were
automatically reconstructed with a variable fil-
Table 1 Details ofpatients and controls
Hoehn Drugs (mglday)
Duration of Onset and Yahr Motor
No Sex Age (y) PD (y) LIR stage UPDRS D P B
Controls
1-6 2M; 4F Mean 58
Range (44-83)
Patients with PD
7 F 65 4 R 1-5 19 200 0 75 -
8 M 76 2 L 1-5 11 50 - -
9 M 68 4-5 R 2 17 400 2 -
10 F 68 3 R 1-5 19 150 1-5
11 M 57 5 R 2 10 300 1-5
12 F 64 2-5 R 2 14 - - -
13 M 69 2 L 2-5 32 - - -
14 F 45 3 R 1 8 - -
15 F 46 2 R 1 15 - -
16 M 54 13 L 2 28 150 15t 3
17 F 58 5 R 2 18 75 -
18 M 46 2 R 1 10 - -
19 M 40 5 R 3 39 - -
20 M 71 21 L 4t 31t 1250 4
21 M 77 23 L 4t 51t 700 4-5
22 F 63 15 R 4t 40t 300 3-5
23 M 71 25 L 4t 39t 375 2-25 -
24 M 57 17 L 4: 55: 1400 4-5 -
PD = Parkinson's disease; Motor UPDRS = motor section of the unified Parkinson's disease rating scale; L = left; R = right;
D = levodopa; P = pergolide; B = biperideen.
*Retrospectively determined onset of parkinsonian signs.
tThis subject received bromocriptine instead of pergolide.
tWorst off values.
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Figure 1 /'23I]FP-CIT SPECT images ofa healthy volunteer (A) and a patient with
Parkinson's disease (B). Transverse slices from the brain at the level of the striatum (about
3 cm above the orbitomeatal line) (L = left side and R = right side). In both images the
level of '23IJFP-CIT activity is colour encodedfrom low (black) via medium (yellow) to
high (white) and scaled (corrected for injected doselkg) to the maximum in the slice of the
control person (maximum is 116 SMU). (A) 66 year old healthy woman, regions of
interest placed in right and left caudate and putamen and occipital cortex; (B) 64 year old
woman with Parkinson's disease, Hoehn and Yahr stage II (patient 12, table 1).
ter, according to the level of counts per slice.
The measured concentration of radioactivity
was expressed as Strichman Medical Units
(SMUs; 1 SMU = 100 Bq/ml as specified by
Strichman Medical Equipment Inc).
SPECT experiments
All subjects received potassium iodide (total
about 266 mg) orally to block thyroid uptake
of free radioactive iodine. After intravenous
injection of 71-126 MBq ["23I]FP-CIT, tomo-
graphic SPECT studies were performed (spe-
cific activity > 93 MBq/nmol; radiochemical
purity > 99%; 123I labelling by Amersham
Cygne BV, Technical University Eindhoven,
The Netherlands, using the trimethylstannyl
precursor of FP-CIT obtained from Research
Biochemicals International, Natick, USA).
On the basis of dosimetry studies performed
in humans, the effective dose equivalent
of [123I]FP-CIT was estimated to be
0 03 mSv/MBq.'9
Pilot time course study
A pilot time course study, in one healthy vol-
unteer and in two patients with Parkinson's
disease, was performed to determine the opti-
mal time postinjection for in vivo DA trans-
porter imaging with 123I FP-CIT. For this
purpose single slice dynamic SPECT
(150-180 s/slice) was performed at the level of
the basal ganglia (orbitomeatal line + 30 mm
dorsally) between 0-60 minutes after injection
This was followed by multislice SPECT at
two, three, and four hours postinjection (for
the volunteer also at five hours postinjection)
starting at and parallel to the orbitomeatal line
(300 s/slice; interslice distance 10 mm; 12
slices or less). The optimum time of acquisi-
tion was defined as the time at which specific
radioactivity in the striatum (total striatal
counts minus counts in the occipital cortex)
was at a stable level. The activity in the occipi-
tal cortex was defined as non-specific activity,
as the occipital cortex is a region nearly devoid
ofDA transporters.26 On the basis of this pilot
study (see results) further tomographic acquisi-
tions were taken at three hours after the injec-
tion of ["23I]FP-CIT. For the groups of healthy
volunteers and patients with Parkinson's dis-
ease, 12 slices or less, starting at and parallel
to the orbitomeatal line were acquired (one
slice at a time; 300 s/slice) with an interslice
distance of 10 mm.
Data processing
For analysis of striatal [123I]FP-CIT binding,
the slice with the highest activity was selected
and a standard template, with regions of inter-
est constructed manually according to a
stereotactic atlas,27 was applied (fig 1). Small
variations of individual brains required move-
ment of the fixed regions of interest, without
changing size and shape, within the template
for optimal fitting. Specific to non-specific
[I12I] FP-CIT binding was then calculated as
[I2'I]FP-CIT Binding = (ROI - OCC)0C c
in wihich ROT repnreseints the- meann radioactivi'ty
(in SMU) in the region of interest (striatum,
putamen, or caudate nucleus) and OCC
depicts the mean radioactivity in the occipital
cortex. This method assumes equal non-spe-
cific uptake in the striatum and occipital cor-
tex. In previous studies this binding ratio
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Figure 2 Radioactivity
in the striatum (V),
occipital cortex (A), and
specific striatal
radioactivity (*) from
0-240 minutes after
injection ofp23I]FP-CIT.
(A) healthy volunteer
(data 300 minutes after
injection not shown); (B)
patient with Parkinson's
disease.
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proved to be a reliable estimate of the so-
called binding potential (Bma/KD).132829 These
binding values were also used to calculate
putamen:caudate nucleus ratios for the ipsilat-
eral and contralateral striatum.
In the patients with Parkinson's disease,
the contralateral striatum was defined as the
side opposite that of initial presentation of
motor signs. For the control subjects, con-
tralateral was arbitrarily assigned to the left
striatum. The binding values were used to cal-
culate relative ipsilateral to contralateral asym-
metry of tracer uptake based on the following
formula:
Asymmetry index ipsilateral contralateralAsymmetryindex = ~x 100
(ipsilateral -
contralateral)/2
For statistical analysis the non-parametric
Mann-Whitney rank sum test (IN-STATrm)
was used. For analysis of the difference in
uptake ratios between ipsilateral and contralat-
eral sides within groups the non-parametric
Wilcoxon paired test was used. All tests were
two tailed with the accepted level of signifi-
cance at P < 0-05.
Results
PILOT TIME COURSE STUDY
There were no subjective or objective adverse
reactions in any subject after injection of
['23I]FP-CIT. The time course of uptake in the
brain of the healthy volunteer showed a grad-
ual accumulation of radioactivity in the stria-
tum during the first two hours after injection,
with a stable level of activity until the end of
the study. Radioactivity in the occipital cortex
accumulated rapidly but started to decline
after 15 minutes, with a stable level of activity
60 minutes after injection until the end of the
study (fig 2). Specific striatal radioactivity
reached a plateau at about two hours after
injection and remained stable until four hours
after injection. The time period between two
and four hours after injection was therefore
considered as a period of pseudoequilibrium.
The striatal uptake in the brain of the patients
with Parkinson's disease showed an initial
peak, but also a stable level of radioactivity
from two hours after injection onwards (fig 2).
Radioactivity in the occipital cortex started to
decline after 15 minutes, with a stable level of
activity after two hours until end of the study. A
similar pattern of specific striatal radioactivity
was found for the patients with Parkinson's
disease compared with the volunteer: a plateau
was reached about 60 minutes after injection
and remained stable until four hours after
injection (fig 2). Therefore, the optimal time
for in vivo DA transporter imaging with 1231.
FP-CIT was set at three hours after injection.
GROUP CHARACTERISTICS
There were no significant age differences
between the controls and groups of patients
with Parkinson's disease (table 1). Within the
Parkinson's disease group, seven patients had
initial left sided motor signs, 11 had right
sided onset (mean duration of disease 8-6;
range 2 to 25 years).
SPECT MEASURES
For all six regions measured (ipsilateral
striatum, contralateral striatum, ipsilateral
caudate, contralateral caudate, ipsilateral
putamen, and contralateral putamen) signifi-
cant lower uptake ratios were found for the
Parkinson's disease group compared with the
control group (P < 0-01, table 2, fig 1). Within
the control group there were no significant dif-
ferences between the ipsilateral and contralat-
eral uptake ratios for the striatum, caudate
nucleus, and putamen. However, within the
Parkinson's disease group the contralateral
uptake ratios were significantly lower than the
ipsilateral uptake ratios for the same three
regions (table 2). Overall average of the asym-
metry index was higher in Parkinson's disease
compared with controls for the putamen
((mean (SEM)) 19 1 (2 4) and 5-6 (1-3)
respectively) and caudate (16-8 (3-4) and 8-6
(2 5) respectively), although it reached signifi-
cance only for the putamen.
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Table 2 Mean (range) ofp23I]PF-CIT SPECT measures in healthy volunteers and patients with Parkinson's disease
All patients Patients with Patients with
Controls with PD early PD non-early PD
n = 6 n = 18 n = 6 n = 12
Striatum:
Contralateral 2-73 (1-87-4-75) 0-98 (0-48-1-82)* 1-29 (1-00-1-82)* 0-83 (0-48-1-81)*t
Ipsilateral 2-62 (1-72-3-92) 1 11 (0 53-2-32)** 1-44 (0-92-2-32)* 0-94 (0-53-1-88)*t4
Caudate:
Contralateral 2 82 (1-92-5-17) 1-38 (0-62-2-55)* 1-84 (1-31-2-55) 1-16 (0 62-2 38)*t
Ipsilateral 2-76 (1-87-4 33) 1-55 (0 53-2-86)*t 2-06 (1-45-2-86)t 1-30 (0 53-2 29)*14
Putamen:
Contralateral 2-51 (1-51-3-92) 0-77 (0-40-1-50)* 1-02 (0O79-1-50)* 0-65 (0 40-1 38)*t
Ipsilateral 2-61 (1-46-4-42) 0 90 (0-35-2 05)*t 1-20 (0 80-2 05)* 0 74 (0-35-1-63)*14
Putamen/caudate ratio:
Contralateral 0-92 (0-79-1 11) 0-58 (0 34-0-93)* 0-57 (0 35-0 74)* 0-59 (0 34-0-93)*
Ipsilateral 0 93 (0-78-1-02) 0-61 (0-39-1-00)* 0 59 (0-39-0-71)* 0 61 (0-40-1-00)*
PD = Parkinson's disease; contralateral is the side opposite that of initial presentation of motor signs. For healthy subjects
contralateral is arbitrarily assigned to the left striatum. All SPECT values are expressed as (region of interest - occipital
cortex)/occipital cortex (range).
*P < 0 05 v controls.
tP < 0 05 v patients with early Parkinson's disease.
tP < 0 05 v contralateral side.
Table 3 Correlation coefficient (Spearman rank correlation) for /23I]FP-CIT SPECT
measures and motor disability scores in patients with Parkinson's disease
Hoehn and Yahr Motor UPDRS
ranking P value rating P value
Striatum:
Contralateral -0 59 0 01 -0 40 0-10
Ipsilateral -0 50 0-03 -0 30 0-23
Caudate:
Contralateral -0-58 0-01 -0 40 0 10
Ipsilateral - 0 49 0 04 -0-27 0-28
Putamen:
Contralateral -0-52 0 03 -0-31 0-22
Ipsilateral -0-48 0-04 - 0-29 0-24
Putamen/caudate ratio:
Contralateral -0-02 0-56 -0-03 0-89
Ipsilateral -0-01 0-97 -0-12 0-63
binding ratio in the caudate nucleus was sig-
nificantly lower than the ipsilateral ratio (table
2).
Moreover, the value of ['23I]FP-CIT bind-
ing in the putamen was lower contralateral to
the side where the motor signs started in five
out of the six patients with early Parkinson's
disease. Overall average of the asymmetry
index was higher in early Parkinson's disease
than controls for the putamen ((mean (SEM)
16-1 (4 3)) and 5-6 (1-3) respectively) and
caudate (10-6 (1-7) and 8-6 (2-5) respec-
In patients with Parkinson's disease binding
of the ligand was decreased more in the puta-
men than in the caudate nucleus, as seen from
the decreased putamen:caudate ratios of bind-
ing values, both for the ipsilateral and the con-
tralateral side compared with those of the
controls. There were no differences in these
ratios between ipsilateral and contralateral
sides within either the control or Parkinson's
disease group (P = 0-84 and P = 061
respectively; table 2).
SPECT MEASURES IN EARLY PARKINSON S
DISEASE
If only a subgroup of six patients with early
Parkinson's disease (defined as patients with
Hoehn and Yahr stage 1 or 1-5 and duration
of disease less than five years; table 1) was
considered for comparison with controls, sig-
nificant differences were still found in four out
of the six binding measures (both ipsilateral
and contralateral for striatum, putamen, and
caudate) presented for all 18 patients with
Parkinson's disease together (table 2). Only
ipsilateral and contralateral caudate uptake
showed no significant difference (P = 018
and P = 009, for ipsilateral and contralateral
caudate respectively; table 2). In patients with
early Parkinson's disease binding of the ligand
was also decreased more in the putamen than
in the caudate nucleus, as measured by the
putamen:caudate ratio of binding values, both
for the ipsilateral and the contralateral side
compared with controls (table 2). For the
entire Parkinson's disease group and the early
Parkinson's disease group the contralateral
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tively), although the difference was not signifi-
cant.
The non-early Parkinson's disease group
(all patients with Parkinson's disease studied
minus the six patients with early Parkinson's
disease) had significantly lower binding than
the early Parkinson's disease group for all six
regions measured (table 2). Finally, there
was no significant difference in age between
the early Parkinson's disease, non-early
Parkinson's disease, and control groups.
CORRELATION OF SPECT SIGNAL WITH HOEHN
AND YAHR STAGE AND UPDRS SCORE
Hoehn and Yahr stage of the patients with
Parkinson's disease was significantly corre-
lated (Spearman rank correlation) with all six
binding measurements (both ipsilateral and
contralateral for the striatum, putamen, and
caudate; table 3, fig 3), whereas putamen:cau-
date ratios were not significantly correlated
with Hoehn and Yahr stage.
Motor UPDRS score had no significant cor-
relation with uptake variables although a ten-
dency for an inverse correlation was noticeable
(table 3, fig 3). Putamen:caudate ratios were
also not significantly correlated with motor
UPDRS score.
Discussion
A major finding of this study is that [123I]FP-
CIT binding in both the caudate nucleus and
putamen (ipsilateral as well as contralateral) of
patients with Parkinson's disease was signifi-
cantly lower compared with age matched con-
trols. The second important finding was the
low ipsilateral and contralateral putamen:cau-
date ratios in patients with Parkinson's dis-
ease. Finally, a subgroup of patients with early
Parkinson's disease showed significantly lower
ipsilateral and contralateral binding in the
putamen, and lower putamen:caudate binding
ratios. The loss of ["23I]FP-CIT uptake in both
the putamen and caudate nucleus in patients
with Parkinson's disease as well as the prefer-
ential loss in the putamen is in agreement with
results from necropsy studies, which disclosed a
more severe depletion of DA in the putamen
than in the caudate nucleus.30 It, moreover,
confirms the recent findings with [1231] 3-CIT
SPECT.'0 This finding is likely due to the
more extensive degeneration in Parkinson's
disease of subpopulations of substantia nigra
cells that project primarily to the putamen
than other nigral cell bodies.' 30-32 The fact that
the decreases of striatal ["23I]FP-CIT reflects
this differential loss in Parkinson's disease
probably indicates the power of brain imaging
with this new radioligand.
In the present study, the time point for in
vivo imaging of the DA transporter with
["23I]FP-CIT was chosen at three hours after
injection-that is, in the period of pseudoequi-
librium. This is in agreement with two other
studies in healthy volunteers, which found
peak uptake of ["23I]FP-CIT into the basal
ganglia three to four hours after injection,'9 or
90% level of the initial peak value of specific
striatal uptake between 80 and 220 minutes
after injection'8 respectively. This one day pro-
tocol seems therefore to allow identification of
DAergic nigrostriatal loss by non-invasive
visualisation of striatal DA transporter con-
tent. This offers a great advantage compared
with the SPECT studies with [1231]/-CIT,
which require imaging acquisition 24 hours
after injection.
Estimation of specific to non-specific bind-
ing ratios gives information about the binding
potential. For ['231] f-CIT it has been sug-
gested that metabolism of this ligand may have
a significant influence on measurement of the
DA transporter with SPECT.33 The metabolic
fate of [123I]FP-CIT has only been studied in
primates.'4 In that study, the major metabolite
of [123I]FP-CIT seemed to be found in the
polar fraction, and the major lipophilic frac-
tion consisted mostly of parent tracer up to
five hours after injection. It is unlikely that the
polar fraction will cross the blood-brain barrier
and subsequently influence the measurement.
However, more accurate measurement of
[123I] FP-CIT uptake in future studies still
requires the investigation of its metabolism in
humans.
The present study shows for the first time
that on application of [123I]FP-CIT a pro-
nounced reduction of striatal DA transporter
binding in patients with Parkinson's disease
can be seen using SPECT. Although this
lower signal most likely reflects degeneration
of the DAergic nigrostriatal neurons (see
above) it should be kept in mind that a possible
down regulation of DA transporter on the
remaining DAergic terminals could perhaps
contribute to the reduction. Compensatory
mechanisms linked to DA cell loss in
Parkinson's disease and animal models of
Parkinson's disease have been described.34 For
example, depletion of tissue DA by chronic
treatment with reserpine in rodents decreased
DA transporter levels.35 So, as the loss of DA
transporters reaches a critical value, it may
perhaps be possible that the remaining
DAergic cells maintain synaptic DA concen-
trations in part by decreasing the available DA
transporters per terminal. Additionally, the
extent to which the density of DA transporters
reflects that of DA terminals is also uncertain.
The transporter-terminal relation may be
altered in patients with Parkinson's disease
compared with controls, as DA transporters
are known to be modulated by concentrations
of endogenous DA.
Until recently most research on the DAergic
deficit in Parkinson's disease in vivo has been
performed with [18F]DOPA PET.4 36 37 Even
more recently, a PET study showed declines
of ['8F]DOPA uptake in early Parkinson's dis-
ease.38 Interestingly, in that study most con-
tralateral putamen KI-values of 11 patients
with hemi-Parkinson's disease of recent onset
fell outside the range of normal values. How-
ever, most ipsilateral putamen ['8F]DOPA
uptake values fell within the normal range.
The authors concluded that either the patients
with early hemi-Parkinson's disease do not
have the disease ipsilaterally, or it is not identi-
fiable with the ['8F]DOPA PET technique. In
138
/23I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease
the present study, the range of individual data
of ['23I]FP-CIT binding in the contralateral
putamen, obtained in a group of patients with
recent onset of hemi-Parkinson's disease, did
not overlap with data obtained from age
matched controls. However, the present study
showed minimal overlap between individual
data of ['23I]FP-CIT binding in the ipsilateral
putamen of the patients with early Parkinson's
disease compared with that of healthy volun-
teers (['23I]FP-CIT binding in the ipsilateral
putamen of only one patient in the early
Parkinson's disease group fell within the nor-
mal range; table 2 does not show individual
data). Importantly, very recently a ['231]f3-CIT
SPECT study also showed bilateral loss of
dopamine transporters in hemi-Parkinson's
disease.39 Based on the results of our study, the
['23I]FP-CIT SPECT technique may be sensi-
tive enough to detect the preclinical period of
Parkinson's disease.
['8F]DOPA PET mainly reflects decarboxy-
lation activity of the presynaptic DAergic ter-
minals, whereas imaging of the presynaptic
DA transporters of the DAergic terminals is
the target for the new PET and SPECT lig-
ands. SPECT studies using ['23I]f -CIT, and
the present study with ['231]FP-CIT, are con-
sistent with PET ['5F]DOPA studies including
the demonstration of greater abnormality of
the putamen compared with the caudate
nucleus, asymmetric uptake, and correlation
with symptom severity.'0 36 However, SPECT
studies with the DA transporter ligands
showed high target to non-target ratios result-
ing in nearly no overlap for the data between
controls and patients with Parkinson's disease.
It is therefore very intriguing to see what PET
studies using these transporter ligands in
patients with Parkinson's disease will show." 12
Preliminary studies with ["C]FP-CIT have
already shown a very high striatal uptake ratio
in healthy volunteers, with an equilibrium in
the striatum attained within the acquisition
time.'7 However, studies in patients with
Parkinson's disease have not been performed
with this new PET ligand.
A source of possible confounding in the
data of the present study lies in the fact that
most of the patients with Parkinson's disease
received DAergic medication. It is possible
that direct or indirect effects of this medica-
tion could have interfered with binding mea-
surements of the DA transporter. However,
Laruelle et al39 showed in baboons that acute
administration of a large dose of levodopa (50
mg/kg intravenously) had no influence on spe-
cific striatal fCIT binding. In the present
study, comparison of striatal ["23I]FP-CIT
binding still showed significantly lower bind-
ing in the six unmedicated patients compared
with the six healthy controls, even though the
average age of the patients was lower. None
the less, the effects of medication were not
considered in this study and should be in the
future.
In conclusion, the present results indicate
that the [123I]FP-CIT SPECT procedure is
very sensitive in discriminating patients with
Parkinson's disease from healthy age matched
volunteers. By contrast with ["23'] 3-CIT
SPECT, in which an adequate image acquisi-
tion could only be obtained 24 hours after
injection, SPECT with FP-CIT can give the
required information by three hours after
injection
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NEUROLOGICAL STAMP
Carl Zeiss (1816-88)
Carl Zeiss studied medicine and was also apprenticed to
various instrument makers in Weimar, Stutgart, and
Vienna. In 1846 he opened a shop in Jena in Germany
which produced and repaired optical equipment. Initially
he specialised in the manufacture of microscopes. In
1866, with Otto Schott and Ernst Abbe, a German
mathematician and physicist, he worked on the micro-
scope, perfecting the homogeneous immersion lens in
1878. The Zeiss workshop soon acquired a world wide
reputation for the manufacture of high quality optical
equipment, embracing every kind of optic instrument but
especially cameras and microscopes.
He was honoured philatelically by East Germany in
1956 on a stamp issued to commemorate the founding of
the 110th Anniversary of the Zeiss Optical Works in Jena.
(Stanley Gibbons E283, Scott 313). Abbe was also hon-
oured on a stamp issued in the same series.
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